Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of malignant pleural effusion.
Chronic malignant pleural exudation is generally characterized by little or no fibrin deposition. However, during induced inflammation, fibrin deposition concomitant with cessation of exudation is seen. To judge the involvement of the fibrinolytic system in this process, concentrations of fibrinolytic factors were followed in 10 patients during treatment by quinacrine instillation and tube drainage. Plasminogen and alpha-2-antiplasmin were found in low concentrations and did not show significant changes during treatment. The plasminogen activator inhibitor PAI-1, which plays an important role in the regulation of fibrinolysis, was also studied during treatment. Before treatment the concentration of PAI-1 was 21.7 +/- 12.0 (mean +/- SD) AU/ml and it increased to 86.9 +/- 25.9 AU/ml 6 h after quinacrine instillation. D-dimer, a product of the lysis of fibrin, was found in high concentrations before treatment (62.7 +/- 25.5 micrograms/ml) and in low concentrations 6 h after treatment (12.2 +/- 7.9 micrograms/ml). Thus, it was possible to demonstrate that the fibrinolytic system is activated during chronic malignant pleural exudation and, furthermore, that the activity decreases during induced inflammation.
Agrenius
V
V
Department of Clinical Chemistry, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
Chmielewska
J
J
Widström
O
O
Blombäck
M
M
D000328:Adult; D000368:Aged; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D015849:Plasminogen Inactivators / Q000378:metabolism; D010994:Pleura / Q000378:metabolism; D010995:Pleural Diseases / Q000188:drug therapy* / Q000209:etiology; D010996:Pleural Effusion / Q000150:complications / Q000188:drug therapy*; D010998:Pleurisy / Q000378:metabolism*; D011796:Quinacrine / Q000627:therapeutic use; D000267:Tissue Adhesions / Q000188:drug therapy* / Q000209:etiology
D005338:Fibrin Fibrinogen Degradation Products; D015849:Plasminogen Inactivators; C036309:fibrin fragment D; D011796:Quinacrine